Literature DB >> 31762142

Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation.

Kesavan Melarcode Ramanan1, Ramya Uppuluri1, Nikila Ravichandran1, Shivani Patel1, Venkateswaran Vellaichamy Swaminathan1, Indira Jayakumar2, Revathi Raj1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31762142     DOI： 10.1002/pbc.28071

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  6 in total

1.  Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Authors:  Romain Lévy; Mathieu Fusaro; Frédéric Guerin; Ahmed Chetouani; Despina Moshous; Alain Fischer; Geneviève de Saint Basile; Fernando E Sepulveda; Bénédicte Neven
Journal:  Blood Adv       Date:  2020-04-14

2.  Treosulfan-Based Conditioning in Matched Family, Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation for Genetic Hemophagocytic Lymphohistiocytosis: Experience and Outcomes over 10 Years from India.

Authors:  Venkateswaran Vellaichamy Swaminathan; Ramya Uppuluri; Satish Kumar Meena; Harika Varla; Rumesh Chandar; Balasubramaniam Ramakrishnan; Indira Jayakumar; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2021-03-06       Impact factor: 0.900

3.  Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985-2016.

Authors:  Satoshi Miyamoto; Katsutsugu Umeda; Mio Kurata; Masakatsu Yanagimachi; Akihiro Iguchi; Yoji Sasahara; Keiko Okada; Takashi Koike; Reo Tanoshima; Masataka Ishimura; Masafumi Yamada; Maho Sato; Yoshiyuki Takahashi; Michiko Kajiwara; Hiroshi Kawaguchi; Masami Inoue; Yoshiko Hashii; Hiromasa Yabe; Koji Kato; Yoshiko Atsuta; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2022-01-04       Impact factor: 8.317

4.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 5.  Primary Immune Regulatory Disorders and Targeted Therapies

Authors:  Burcu Kolukısa; Safa Barış
Journal:  Turk J Haematol       Date:  2021-01-14       Impact factor: 1.831

Review 6.  Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

Authors:  Camille Keenan; Kim E Nichols; Sabrin Albeituni
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.